Solventum (SOLV) Q4 2025 earnings review
Transformation Bears Fruit, but Cash Flow Remains Obscured by Spin-off Costs
Solventum closed out its first full fiscal year as an independent company with solid top-line momentum, delivering 3.5% organic sales growth in Q4. A reported revenue decline of 3.7% simply reflects the strategic divestiture of the Purification and Filtration (P&F) business. The sale's proceeds transformed the balance sheet, wiping out nearly $2.8 billion in debt and powering an 11% YoY increase in Adjusted EPS to $1.57. However, the heavy lifting of the 3M separation continues to punish cash flow and gross margins. With a $500M restructuring program underway to offset tariff pressures, FY26 guidance paints a picture of a company successfully defending its core operations while structurally repositioning for long-term growth.
🐂 Bull Case
The successful sale of the P&F segment drastically de-levered the company, reducing long-term debt from $7.8B to $5.0B. Lower interest expenses immediately boosted EPS and shifted capital allocation optionality toward tuck-in M&A, evidenced by the December acquisition of Acera.
Before the spin-off, the portfolio suffered years of volume declines. Solventum has now printed five consecutive quarters of positive organic growth, guided for another 3-4% underlying expansion in FY26 (excluding planned SKU exits).
🐻 Bear Case
FY25 Free Cash Flow was severely negative (-$10M) down from +$805M a year ago. Even with FY26 guidance pointing to ~$200M, cash conversion remains severely suppressed by massive, multi-year ERP implementations and public company stand-up costs.
GAAP Gross margin collapsed 260 basis points YoY in Q4 to 51.4%. Elevated supply agreement markups with 3M and global tariff pressures are forcing management into defensive cost-cutting simply to maintain the ~20% operating margin floor.
⚖️ Verdict: ⚪
Neutral/Bullish. Management is executing exactly what they promised: stabilizing volumes, selling non-core assets to pay down debt, and revamping commercial operations. The depressed cash flow is a structural reality of the spin-off, but patient investors are watching the core earnings engine quietly accelerate.
Key Themes
P&F Divestiture Transforms the Balance Sheet
The defining financial event of FY25 was the September sale of the Purification and Filtration segment. The cash proceeds allowed Solventum to immediately extinguish roughly $2.8 billion of long-term debt. This pivotal move structurally permanently reduces interest expense, creating a massive tailwind for bottom-line profitability and clearing the runway for management to begin pursuing tuck-in acquisitions.
Gross Margins Buckling Under Tariffs and Stand-up Costs
Despite strong volume growth, profitability at the top of the income statement is deteriorating. Q4 GAAP Gross Margin fell to 51.4% from 54.0% a year prior. Management previously guided to $60-$80M in tariff headwinds, and SG&A expenses surged 10.7% for the full year. The newly announced $500M 'Transform for the Future' restructuring program is a necessary defensive maneuver to protect the bottom line from these macro pressures.
Protracted Free Cash Flow Weakness
The sheer cost of separating from 3M—including global ERP cutovers and facility transitions—has temporarily ruined Solventum's cash generation profile. Operating cash flow dropped 56% in Q4 alone. While underlying conversion is healthy when ignoring one-time items, investors must endure at least another year of weak reported cash flow before these structural drags roll off in 2027.
Dental and HIS Segments Lead the Organic Charge
Dental Solutions was the standout growth driver in Q4, delivering 5.9% organic growth on the back of new product launches (Clarity, Filtek). Meanwhile, the Health Information Systems (HIS) segment grew 3.2% organically while boasting a massive 38.3% operating margin. As long as these two segments outperform, they provide a highly profitable counterweight to slower growth in Advanced Wound Care (+1.7%).
SKU Rationalization Creates a Top-Line Drag
Management's plan to exit thousands of unprofitable SKUs is a smart long-term strategy for supply chain simplification, but it masks the true speed of the turnaround. The ongoing exit represents an estimated ~100 basis point headwind to reported top-line growth in FY26, requiring investors to continuously mentally bridge reported results with 'underlying' momentum.
Other KPIs
Accelerating significantly from 34.1% in the prior year quarter. HIS remains the most profitable unit in the portfolio. Revenue cycle management tools, particularly AI-driven autonomous coding, are proving to be highly scalable software revenues that pull up the entire corporate margin profile.
Up 10.7% YoY. This is the visual footprint of a new public company standing on its own two feet. The massive jump reflects duplicated infrastructure from the 3M split, establishing new distribution centers, and the early costs of their multi-year restructuring programs.
Guidance
Stable. The headline number appears slightly slower than FY25's 3.3% rate, but explicitly absorbs a ~100 bps headwind from strategic SKU exits. The underlying operations are guided to accelerate slightly to the 3.0%-4.0% range, inching closer to their 4-5% Long Range Plan.
Accelerating. Implies roughly 6.4% growth at the midpoint compared to FY25's $6.11. This bottom-line expansion is largely mechanically driven by the absence of massive interest payments following the P&F debt paydown, overriding margin pressures at the gross profit level.
Reversing. Moving back into positive territory after printing negative $10M in FY25. However, this is still profoundly low relative to the company's $1B+ Adjusted Net Income run-rate, indicating that peak cash burn for separation activities (like IT and European ERP migrations) remains a severe near-term reality.
Key Questions
Free Cash Flow Bridge
Your FY26 free cash flow guidance of ~$200 million remains a fraction of projected adjusted net earnings. Can you quantify the exact cash headwinds expected from separation costs versus core working capital needs in 2026?
Margin Protection Confidence
GAAP Gross margins compressed significantly in Q4. With $60-80M in tariff headwinds lingering, how much of your new $500M 'Transform for the Future' savings do you expect to recognize in FY26 to defend operating margins?
Acquisitions & Capital Allocation
With the debt drastically reduced, you closed the acquisition of Acera in December. What is the expected financial contribution from Acera in FY26, and how aggressive will your tuck-in M&A posture be moving forward?
Advanced Wound Care Deceleration
Advanced Wound Care organic growth lagged the broader MedSurg segment at just 1.7% in Q4. Has the voluntary product recall mentioned in Q2 fully resolved, or are there lingering commercial challenges in this sub-segment?